Autonomix medical, inc. reports positive outcomes in initial phase of first-in-human proof-of-concept trial in pancreatic cancer pain and initiates market expansion study for visceral cancer pain

Initial trial phase (“poc 1”) achieved key learnings and met all study objectives clinically meaningful pain reduction with 100% of responders achieving zero opioid use at 7 days post-procedure and 73% of responders remaining opioid free at 4-6 week follow-up company has initiated market expansion study (“poc 2”) of additional visceral cancers, and earlier stage pancreatic cancer, to begin in q2 2025 additional indications potentially double the addressable market beyond pancreatic cancer pain the woodlands, tx, april 30, 2025 (globe newswire) -- autonomix medical, inc. (nasdaq: amix) (“autonomix” or the “company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today provided an update on the initial trial phase of its first-in-human proof-of-concept trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with severe pancreatic cancer pain. the company enrolled twenty (20) patients in poc 1, including the first five (5) “lead-in” patients.
AMIX Ratings Summary
AMIX Quant Ranking